R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal ArticleDOI
High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.
Bei Hu,Peter F. Thall,Denái R. Milton,Koji Sasaki,Qaiser Bashir,Nina Shah,Krina K. Patel,Uday R. Popat,Chitra Hosing,Yago Nieto,Pei Lin,Ruby Delgado,Jeffrey L. Jorgensen,Elisabet E. Manasanch,Donna M. Weber,Sheeba K. Thomas,Robert Z. Orlowski,Richard E. Champlin,Muzaffar H. Qazilbash +18 more
TL;DR: Despite bortezomib-based induction, upfront auto-HSCT, and use of maintenance therapy, PFS and OS remained worse in MRD+ and HRD patients.
Journal ArticleDOI
Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
Jatin J. Shah,Lei Feng,Elisabet E. Manasanch,Donna M. Weber,Sheeba K. Thomas,Francesco Turturro,Nina Shah,Uday R. Popat,Yago Nieto,Qaiser Bashir,Silvia C. Munoz,Ashley Landry,Kathleen Mendoza,Richard E. Champlin,Muzaffar H. Qazilbash,Robert Z. Orlowski +15 more
TL;DR: A phase II dose expansion was pursued to further explore the potential improvement in depth of response with RVD + pano in newly diagnosed myeloma (NDMM) and to determine the safety/tolerability of pano and RVD in NDMM.
Journal ArticleDOI
Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial
Uday R. Popat,Rohtesh S. Mehta,Roland L. Bassett,Piyanuch Kongtim,Piyanuch Kongtim,Julianne Chen,Amin M. Alousi,Paolo Anderlini,Stefan O. Ciurea,Chitra Hosing,Roy B. Jones,Partow Kebriaei,Issa F. Khouri,Richard Lindsay,Yago Nieto,Amanda Olson,Betul Oran,Muzaffar H. Qazilbash,Gabriela Rondon,Elizabeth J. Shpall,Srdan Verstovsek,Borje S. Andersson,Richard E. Champlin +22 more
TL;DR: Intensifying Bu-Flu regimen using pharmacokinetic-monitoring appears promising in reducing relapse without increasing non-relapse mortality in older patients with myelofibrosis.
Journal ArticleDOI
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Yago Nieto,Peter F. Thall,Junsheng Ma,Benigno C. Valdez,Sairah Ahmed,Paolo Anderlini,Uday R. Popat,Roy B. Jones,Elizabeth J. Shpall,Chitra Hosing,Muzaffar H. Qazilbash,Partow Kebriaei,Amin M. Alousi,Melissa Timmons,Alison M. Gulbis,Alan L. Myers,Yasuhiro Oki,Michelle A. Fanale,Bouthaina S. Dabaja,Chelsea C. Pinnix,Sarah A. Milgrom,Richard E. Champlin,Borje S. Andersson +22 more
TL;DR: The data show that Gem/Bu/Mel is safe, in this nonrandomized comparison yielding improved outcomes compared with a concurrently treated and prognostically matched cohort of patients with primary refractory or poor-risk relapsed HL receiving BEAM.
Journal ArticleDOI
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years.
Catherine Kendall Major,Hagop M. Kantarjian,Koji Sasaki,Gautam Borthakur,Tapan M. Kadia,Naveen Pemmaraju,Courtney D. DiNardo,Nicholas J. Short,Naval Daver,Elias Jabbour,Richard E. Champlin,Guillermo Garcia-Manero,Marina Konopleva,Michael Andreeff,Steven M. Kornblau,William G. Wierda,Sherry Pierce,Farhad Ravandi,Jorge E. Cortes +18 more
TL;DR: A retrospective analysis of AML patients treated with chemotherapy only or chemotherapy’+ hematopoietic cell transplant (HCT) who maintained their first complete remission for ≥3 years found long-term AML survivors need routine monitoring for comorbidities, secondary malignancies, and late relapses.